Congress Considers Pay Hike To Retain Top Biomedical Scientists In Government

WASHINGTON—Pressure has been building in Congress to provide higher pay for federal biomedical researchers. But it’s unlikely that any of three bills currently under congressional scrutiny—one of them a well-publicized proposal from President Bush that applies to employees at all government agencies—will make it into law this year. The driving force behind all three of the plans is a desire on the part of federal agencies such as the National Institutes of Health to

Written byElizabeth Pennisi
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

WASHINGTON—Pressure has been building in Congress to provide higher pay for federal biomedical researchers. But it’s unlikely that any of three bills currently under congressional scrutiny—one of them a well-publicized proposal from President Bush that applies to employees at all government agencies—will make it into law this year.

The driving force behind all three of the plans is a desire on the part of federal agencies such as the National Institutes of Health to recruit and retain an elite cadre of scientists.

But the proposals face serious opposition from those who don’t want to see scientists’ pay scales treated differently from the pay scales of other federal workers. Those in opposition thus favor maintaining the existing linkage in salary among all government employees.

“This [legislation] breaks that link,” says Michael MilIman, who directed an Institute of Medicine study that evaluated the future of the NIH intramural program. “So it’s a ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies